Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)

The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM). Adult patients with T2DM...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2010-05, Vol.9 (1), p.20-20, Article 20
Main Authors: Bardini, Gianluca, Giorda, Carlo B, Pontiroli, Antonio E, Le Grazie, Cristina, Rotella, Carlo M
Format: Article
Language:English
Subjects:
Aged
Anticholesteremic Agents - administration & dosage
Azetidines - administration & dosage
Biomarkers - blood
Blood Glucose - metabolism
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Coronary Disease - blood
Coronary Disease - drug therapy
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Double-Blind Method
Drug Combinations
Ezetimibe, Simvastatin Drug Combination
Female
Glycated Hemoglobin - metabolism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Italy
Male
Middle Aged
Odds Ratio
Original investigation
Risk Assessment
Risk Factors
Simvastatin - administration & dosage
Time Factors
Treatment Outcome
Triglycerides - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM). Adult patients with T2DM and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C >or= 2.6 mmol/L (100 mg/dL) and
ISSN:1475-2840
1475-2840
DOI:10.1186/1475-2840-9-20